BIO Events
PACE: Downstream effects of IRA on patients
Three years after the passage of the Inflation Reduction Act (IRA), patient advocates and the biotech industry are working to navigate downstream negative impacts on ...
November 11, 2025
Read More
Latest News
PACE: Downstream effects of IRA on patients
November 11, 2025
PACE panel urges incentives for exciting new GTT drugs
November 10, 2025
PACE: How 340B outgrew its goal and stopped helping patients
November 4, 2025
BIO CEO John Crowley tells Senate how to support biotech
November 3, 2025
BIO brings together patient advocates and industry at PACE
October 27, 2025
LATEST STORIES
BIO Events
PACE: Downstream effects of IRA on patients
Three years after the passage of the Inflation Reduction Act (IRA), patient advocates and the biotech industry are working to navigate downstream negative impacts on ...
November 11, 2025
Federal Policy
PACE panel urges incentives for exciting new GTT drugs
Luke Rosen had hoped a new treatment would slow the progression of his daughter’s KIF1A Associated Neurological Disorder (KAND), but was amazed to see an ...
November 10, 2025
BIO Events
PACE: How 340B outgrew its goal and stopped helping patients
The 340B program, in recent decades, has shown how the best laid plans can go sideways when not kept transparent and properly in check. Initially ...
November 4, 2025
WHAT YOU MISSED AT THE LATEST BIO EVENTS
PACE: Downstream effects of IRA on patients
Three years after the passage of the Inflation Reduction Act (IRA), patient advocates and the biotech industry are working to navigate downstream negative impacts on ...
November 11, 2025
Read More
PACE: How 340B outgrew its goal and stopped helping patients
The 340B program, in recent decades, has shown how the best laid plans can go sideways when not kept transparent and properly in check. Initially ...
November 4, 2025
Read More










